Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez

Annals of the Rheumatic Diseases

Volumn 78, Issue 11, 2019, Pages

  Khanna, Dinesh ^a   Jahreis, Angelika ^b   Lin, Celia J F ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b GENENTECH INC   (United States)

Author keywords

CLINICAL TRIAL; disease activity; pulmonary fibrosis; systemic sclerosis; tocilizumab

Indexed keywords

TOCILIZUMAB; MONOCLONAL ANTIBODY;

CLINICAL EFFECTIVENESS; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; PATIENT RISK; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC;

EID: 85055508567     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-214477     Document Type: Letter

References (5)

1. Narváez J, LLuch J, Alegre Sancho JJ, et al. Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: A case series. Ann Rheum Dis 2019;78: E123.
2. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial. The Lancet 2016;387: 2630-40.
3. Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018;77: 212-20.
4. De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013;40: 435-46.
5. Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study. Ann Rheum Dis 2014;73: 1340-9.